These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11252930)

  • 1. Immunotherapy for non-Hodgkin's lymphoma.
    Vose JM
    Oncology (Williston Park); 2001 Feb; 15(2):141-7, 151; discussion 152-5. PubMed ID: 11252930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
    Maloney DG
    J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
    J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review].
    Lu PP; Meng ZY; Zhou MX; Wang MW; Dou GF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1258-61. PubMed ID: 17204206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
    Reinis M
    Curr Opin Mol Ther; 2007 Jun; 9(3):291-8. PubMed ID: 17608028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospects.
    Renner C; Trümper L; Pfreundschuh M
    Leukemia; 1997 Apr; 11 Suppl 2():S55-9. PubMed ID: 9178842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.
    Koumarianou A; Kountourakis P; Economopoulos T
    J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):230-2. PubMed ID: 18406604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates.
    Press OW
    Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S19-26. PubMed ID: 9672771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations.
    Caspar CB; Levy S; Levy R
    Blood; 1997 Nov; 90(9):3699-706. PubMed ID: 9345055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
    Hurvitz SA; Timmerman JM
    Curr Opin Oncol; 2005 Sep; 17(5):432-40. PubMed ID: 16093791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of B-cell lymphoma using peptides. A novel concept.
    Lam KS
    West J Med; 1993 May; 158(5):475-9. PubMed ID: 8342262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epratuzumab: targeting B-cell malignancies through CD22.
    Coleman M; Goldenberg DM; Siegel AB; Ketas JC; Ashe M; Fiore JM; Leonard JP
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3991S-4S. PubMed ID: 14506198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.
    Foon KA
    N Engl J Med; 1982 Sep; 307(11):686-7. PubMed ID: 6981064
    [No Abstract]   [Full Text] [Related]  

  • 15. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies.
    Meeker T; Lowder J; Cleary ML; Stewart S; Warnke R; Sklar J; Levy R
    N Engl J Med; 1985 Jun; 312(26):1658-65. PubMed ID: 3923352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of adult non-Hodgkin's lymphomas.
    Gobbi PG; Cavalli C
    Haematologica; 1986; 71(4):321-43. PubMed ID: 2430865
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.
    Timmerman JM
    Adv Pharmacol; 2004; 51():271-93. PubMed ID: 15464914
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness.
    Ashour AK; Petersen JL; McIlhaney MM; Vose JM; Solheim JC
    Hybridoma (Larchmt); 2006 Oct; 25(5):306-8. PubMed ID: 17044787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.
    Miller RA; Maloney DG; Warnke R; Levy R
    N Engl J Med; 1982 Mar; 306(9):517-22. PubMed ID: 6173751
    [No Abstract]   [Full Text] [Related]  

  • 20. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR
    Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.